Last reviewed · How we verify
NCT03991975
Study of TQB2450 Combined With Anlotinib in Subjects With Advanced Acral Malignant Melanoma
Phase 1, PHASE2 trial testing Anlotinib in Advanced Acral Malignant Melanoma in 42 participants. Status unknown.
31 March 2020
Quick facts
| Lead sponsor | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 42 |
| Start date | 11 June 2019 |
| Primary completion | 31 March 2020 |
| Estimated completion | 31 December 2021 |
| Sites | 1 location across China |
Drugs / interventions tested
- Anlotinib — full drug profile →
- TQB2450
Conditions studied
- Advanced Acral Malignant Melanoma — all drugs for Advanced Acral Malignant Melanoma →
Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. — full company profile →
Who can join
Adults 18 to 75, any sex, with Advanced Acral Malignant Melanoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Immunotherapy in Acral and Mucosal Melanoma: Current Status and Future Directions.
Mao L, Qi Z, Zhang L, Guo J, et al · · 2021 · cited 119× · PMID 34149718 · DOI 10.3389/fimmu.2021.680407 -
Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy.
Rose AAN, Armstrong SM, Hogg D, Butler MO, et al · · 2021 · cited 36× · PMID 33483342 · DOI 10.1136/jitc-2020-001642 -
Emerging strategies to treat rare and intractable subtypes of melanoma.
Alicea GM, Rebecca VW. · · 2021 · cited 30× · PMID 32274887 · DOI 10.1111/pcmr.12880 -
The future of targeted kinase inhibitors in melanoma.
Caksa S, Baqai U, Aplin AE. · · 2022 · cited 25× · PMID 35513054 · DOI 10.1016/j.pharmthera.2022.108200 -
Acral melanoma: new insights into the immune and genomic landscape.
Carvalho LAD, Aguiar FC, Smalley KSM, Possik PA. · · 2023 · cited 21× · PMID 37913653 · DOI 10.1016/j.neo.2023.100947 -
Immune Checkpoint Inhibitors in Advanced Acral Melanoma: A Systematic Review.
Zheng Q, Li J, Zhang H, Wang Y, et al · · 2020 · cited 21× · PMID 33344255 · DOI 10.3389/fonc.2020.602705 -
Multidisciplinary approach and treatment of acral and mucosal melanoma.
Fortuna A, Amaral T. · · 2024 · cited 11× · PMID 38469235 · DOI 10.3389/fonc.2024.1340408 -
Thinking Small: Small Molecules as Potential Synergistic Adjuncts to Checkpoint Inhibition in Melanoma.
Chacon AC, Melucci AD, Qin SS, Prieto PA. · · 2021 · cited 9× · PMID 33810078 · DOI 10.3390/ijms22063228
Verify or expand the search:
- PubMed search for NCT03991975
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Anlotinib
Trials testing the same drug.
- NCT07470840 — SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma · Phase 2 · not yet recruiting
- NCT07537777 — Benmelstobart Plus Anlotinib Combined With SBRT for Patients With Hepatocellular Carcinoma Failing First-Line Targeted T · Phase 2 · not yet recruiting
- NCT07320963 — Chidamide in Combination With Toripalimab and Anlotinib in Recurrent/Metastatic Nasopharyngeal Carcinoma. · Phase 1, PHASE2 · not yet recruiting
- NCT07388875 — Sacituzumab Tirumotecan Plus Anlotinib in Previously Treated ES-SCLC · Phase 2 · not yet recruiting
- NCT07376499 — Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum a · Phase 2 · not yet recruiting
Other Chia Tai Tianqing Pharmaceutical Group Co., Ltd. trials
Trials by the same sponsor.
- NCT06990776 — A Clinical Trial to Evaluate the Efficacy and Safety of TQA3605 Tablets in Treatment-naive Chronic HBV-infected Subjects · Phase 2 · withdrawn
- NCT06851442 — Clinical Trial of Evaluating TQB3912 Tablets Combined With Fulvestrant Injection±TQB3616 Capsules for Locally Advanced o · Phase 1, PHASE2 · terminated
- NCT06711991 — A Clinical Trial of TQC3927 Powder for Inhalation in Chronic Obstructive Pulmonary Disease · Phase 1 · completed
- NCT06672276 — To Evaluate the Pharmacokinetics and Safety of TQD3606 for Injection in Subjects With Renal Insufficiency · Phase 1 · completed
- NCT06644417 — Clinical Study of TQA3605 Tablets Combined With Nucleoside (Acid) Analogs (NAs) Drugs Compared With NAs Drugs in the Tre · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03991975 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Last refreshed: 30 October 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03991975.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing